Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Cat.No. : CSC-RR0381 Host Cell: BXPC-3
| Cat. No. | CSC-RR0381 |
| Description | This cell line is engineered to stably overexpress the Luciferase in BXPC-3 cells. |
| Introduction | BXPC-3-Luc cell line is constructed by stable integration of luciferase encoding gene into BXPC-3 cell genome. It is a good cell model for in vitro or in vivo cancer research. |
| Gene | Luciferase |
| Host Cell | BXPC-3 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Protein localization 3. Drug screening and toxicology 4. Live cell imaging |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Source | BXPC-3 |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
One of the most aggressive cancers still is pancreatic cancer (PC), which is defined by a bad prognosis and few treatment choices. To improve diagnostic and therapy effectiveness, researchers have been investigating molecular markers and focused treatments. In this setting, a recent work examined the function of microRNA-543 in PC, including its interaction with the serine/threonine kinase STK31 and the long non-coding RNA LINC00847. Using the BxPC-3 cell line, researchers clarified the fundamental processes controlling cell proliferation, invasion, and death using Western blotting, quantitative real-time PCR, and luciferase reporter assays. The findings revealed that low levels of microRNA-543 correlate with increased expression of STK31 and LINC00847, highlighting a potential pathway for therapeutic intervention.
Figure 1. The researchers used qRT-PCR and Western blotting to analyze STK31 expression in pancreatic cancer tissues and BxPC-3 cells, exploring its interaction with microRNA-543. (Liu Y, et al., 2023)
Creative Biogene's luciferase Reporter Cell Line, based on the BXPC-3 model, is designed for similar investigative purposes. This cell line can facilitate the study of gene regulation and signaling pathways in pancreatic cancer research, especially in relation to microRNA functions and their molecular targets. By integrating our luciferase reporter technology, researchers can easily monitor transcriptional activity and understand the dynamic interactions between microRNAs and their targets.
A: The Luciferase Reporter Cell Line - BXPC-3 serves as a valuable tool for investigating pancreatic cancer progression and therapeutic response. By expressing luciferase, researchers can quantitatively monitor tumor growth and metastasis in vivo using bioluminescence imaging. This allows for the evaluation of experimental therapies and the identification of potential treatments for pancreatic cancer.
A: The Luciferase Reporter Cell Line - BXPC-3 offers several advantages over traditional cell lines in studying pancreatic cancer biology. Firstly, its stable expression of luciferase enables longitudinal monitoring of tumor growth and metastasis in vivo, providing insights into disease progression. Secondly, BXPC-3 cells retain characteristics of pancreatic cancer cells, making them a relevant model for investigating disease mechanisms and therapeutic interventions.
A: In investigating the efficacy of novel chemotherapeutic agents for pancreatic cancer treatment, the Luciferase Reporter Cell Line - BXPC-3 can be used to evaluate tumor response in preclinical studies. Researchers can administer candidate drugs to mice bearing BXPC-3 xenograft tumors and monitor changes in luciferase activity over time using bioluminescence imaging. This allows for the identification of promising drug candidates for further development.
A: The Luciferase Reporter Cell Line - BXPC-3 is instrumental in studying the tumor microenvironment of pancreatic cancer. By co-culturing BXPC-3 cells with stromal cells or immune cells, researchers can investigate the interactions between tumor cells and the surrounding microenvironment. Luciferase expression enables quantification of changes in tumor growth and response to microenvironmental cues or therapeutic interventions, providing insights into disease progression and treatment strategies.
A: Generating stable luciferase-expressing cell lines with the Luciferase Reporter Cell Line - BXPC-3 involves transfecting the cells with a luciferase expression vector, followed by selection with antibiotics or selection markers. Clonal selection may be performed to isolate individual clones with stable luciferase expression. These clones can then be expanded and characterized for their luciferase activity before experimental use in studying pancreatic cancer biology and therapy.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The BXPC-3 cells are relatively easy to culture and maintain, ensuring that the Luciferase Reporter Cell Line - BXPC-3 is accessible for continuous use in various experimental conditions, reducing the complexity of long-term studies.
United States
03/11/2023
Luciferase assays are quick and straightforward, meaning the Luciferase Reporter Cell Line - BXPC-3 can deliver rapid results, accelerating the experimental workflow and facilitating high-throughput screening.
Canada
12/21/2023
With the Luciferase Reporter Cell Line - BXPC-3, we can efficiently screen for therapeutic agents by measuring changes in luciferase activity, making it an excellent tool for drug discovery in pancreatic cancer.
Canada
04/01/2023
The Luciferase Reporter Cell Line - BXPC-3 provides quantifiable luminescent output, enabling precise measurement of cellular activities that correlate with luciferase expression, essential for reproducible results and accurate data analysis.
Germany
12/29/2020
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.